We thank Yutaka Shimazu for his insightful comments. We agree that our positive findings1–4 highlight the urgent need for further work on biomarkers of neuronal damage and immune mechanisms in ...
Iovance Biotherapeutics (($IOVA)) announced an update on their ongoing clinical study. Study Overview: Iovance Biotherapeutics is conducting a ...
Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, ...
High-dose interleukin-2 (IL-2) induces responses in 15% to 20% of patients with advanced melanoma; 5% to 8% are durable complete responses (CRs). The HLA-A2–restricted, modified gp100 peptide (210M) ...
On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at ...
Purpose: Previous preclinical and clinical studies have demonstrated that autologous tumor vaccines can induce relatively specific tumor-reactive T cells in draining lymph nodes. The adoptive transfer ...
Interleukin-2 (IL-2) is a vital cytokine in adoptive cell therapy that plays an important part in the stimulation and growth of immune cells as well as Tumor-Infiltrating Lymphocytes (TIL), Chimeric ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients ...
BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, ...
In the MIROCALS trial, Gilbert Bensimon and colleagues1 showed that low-dose interleukin-2 (IL-2) added to riluzole did not significantly reduce mortality in an unadjusted analysis of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback